Efficacy of icotinib in advanced lung squamous cell carcinoma

Efficacy of icotinib in advanced lung squamous cell carcinoma

Abstract Background There are controversial data supporting the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with advanced lung squamous cell carcinoma (SCC). In this study, the efficacy of icotinib in unselected and EGFR‐mutated patients with lun...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shuai Liang, Yan Xu, Fenlai Tan, Lieming Ding, Yongbin Ma, Mengzhao Wang
Format:	Article
Language:	English
Published:	Wiley 2018-09-01
Series:	Cancer Medicine
Subjects:	adenocarcinoma EGFR EGFR‐TKIs icotinib squamous cell carcinoma
Online Access:	https://doi.org/10.1002/cam4.1736
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer
by: Lu Xia, et al.
Published: (2025-07-01)

Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma
by: Weijiao Xu, et al.
Published: (2025-04-01)

The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment
by: Nicha Zungsontiporn, et al.
Published: (2025-08-01)

Proteomic Profiling Reveals TPR and FGA as Predictive Serum Biomarkers of Relapse to First- and Second-Generation EGFR-TKIs in Advanced Lung Adenocarcinoma
by: Pritsana Raungrut, et al.
Published: (2025-06-01)

Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects
by: Qinglin Shen, et al.
Published: (2025-05-01)

First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-07-01)

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
by: Ilaria Marrocco, et al.
Published: (2021-03-01)

MCAM interacts with integrin β1 to promote EGFR-TKI resistance in lung adenocarcinoma through the JAK3 signalling pathway
by: Saiqun Zhang, et al.
Published: (2025-07-01)

Discovery of BBT-176 as a fourth-generation EGFR tyrosine kinase inhibitor
by: Krishna Babu Duggirala, et al.
Published: (2025-07-01)

EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study
by: Sen Yang, et al.
Published: (2025-05-01)

Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes
by: Meng Zhang, et al.
Published: (2025-08-01)

Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
by: E. V. Levchenko, et al.
Published: (2023-02-01)

RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE)
by: L. Yu. Vladimirova, et al.
Published: (2016-04-01)

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
by: Tao Yu, et al.
Published: (2020-05-01)

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway
by: Han Wang, et al.
Published: (2024-05-01)

A comprehensive comparison of third generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment efficacy and adverse events: A Bayesian meta-analysis
by: Jinyu Yu, PhD, et al.
Published: (2025-09-01)

A study on the prediction of targeted therapy efficacy in advanced lung adenocarcinoma patients with EGFR mutations using CT-based delta-radiomics model
by: Zekai Wu, et al.
Published: (2025-05-01)

Severe hypotension induced by Almonertinib: a case report with literature review and clinical insights
by: Haiyu Niu, et al.
Published: (2025-07-01)

GLUT1 sensitizes tumor cells to EGFR-TKIs by binding with activated EGFR and regulating its downstream signaling pathways
by: Zhangrong Xie, et al.
Published: (2025-05-01)

Activation of different growth factor systems in tissues of adenocarcinoma and signet-ring cell carcinoma of the stomach
by: O. I. Kit, et al.
Published: (2019-12-01)

Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
by: Linwu Kuang, et al.
Published: (2025-03-01)

Analysis and characterization of chondroitin/dermatan sulfate composition of lung adenocarcinoma tissues with different types of genetic alterations in ALK, EGFR and KRAS oncogenes
by: Domonkos Pál, et al.
Published: (2025-06-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)

EGFR-mutant lung adenocarcinoma transformed into small cell Lung cancer: A case report and literatures review
by: Jinhong Chen, et al.
Published: (2025-01-01)

Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia
by: Noni Novisari Soeroso, et al.
Published: (2025-01-01)

Salivary EGF: EGFR ratio as potential early diagnostic biomarker for oral cancer detection in tobacco chewers: a preliminary cross-sectional study
by: Ruchika Kaul-Ghanekar, et al.
Published: (2025-04-01)

Features of some growth factors content in tumors and blood plasma in patients with rare forms of endometrial cancer
by: E. M. Frantsiyants, et al.
Published: (2025-06-01)

Risk factors for radiation pneumonitis in NSCLC patients treated with third-generation EGFR TKIs and chest radiotherapy
by: Nan Zhao, et al.
Published: (2025-05-01)

A Case of Lung Cancer Exhibiting Pleoymorphic Carcinoma Transformation Resistance Following Treatment With Osimertinib That Was Successfully Treated Using Local Ablative Treatment
by: Yoshiaki Nagai, et al.
Published: (2025-01-01)

Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC)
by: Purvish M. Parikh, et al.
Published: (2025-01-01)

Triple reversal phenomenon in EGFR-mutant lung adenocarcinoma with prostate metastasis following hepatocellular carcinoma: a rare Case Report with diagnostic and therapeutic implications
by: Jieyan Luo, et al.
Published: (2025-07-01)

Lung Adenocarcinoma with EGFR Exon 20 H773_V774delinsLM Mutation  Sensitive to Furmonertinib: A Case Report
by: Rongzhen LI, et al.
Published: (2025-06-01)

Postoperative radiotherapy improves disease-free survival of EGFR wild-type pN2 non-squamous-cell non-small-cell lung cancer (Nsq-NSCLC) patients after complete resection: a propensity score matching analysis
by: Yunsong Liu, et al.
Published: (2025-03-01)

Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI
by: Yiming ZENG, et al.
Published: (2025-06-01)

Interleukin 21-Armed EGFR-VHH-CAR-T Cell Therapy for the Treatment of Esophageal Squamous Cell Carcinoma
by: Chenglin Zhang, et al.
Published: (2025-06-01)

Modern Trends of Radiotherapy Cancer Oral Cavity
by: V. A. Titova, et al.
Published: (2016-11-01)

Response of EGFR-mutated pulmonary pleomorphic carcinoma to pembrolizumab
by: Yuki Hatakeyama, et al.
Published: (2025-01-01)

An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer
by: Yongfeng Yu, et al.
Published: (2025-07-01)

Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study
by: Laura S. Puuniemi, et al.
Published: (2025-07-01)

Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study
by: Johanne Elise Nyen, et al.
Published: (2025-02-01)